EXHIBIT 10.43
January 22, 2002
Mr. Xxxx Xxxxxx
Xxxx Xxxxx Cancer Institute
0000 Xxxxx Xxxxxx Xxxxxxxxx
Xxxxx Xxxxxx, XX 00000
Re: Master Services Agreement between CancerVax Corporation
("CancerVax"), the Xxxx Xxxxx Cancer Institute ("JWCI") and
Synteract, Inc. ("Synteract"), dated January __, 2002 (the
"Master Agreement")
Dear Xxxx:
This letter agreement (the "Letter Agreement"), which is made and
entered into as of the __ day of January, 2002, between JWCI and CancerVax, is
intended to allocate financial responsibility between the parties hereto for
fees and expenses charged by Synteract in connection with the provision of the
Services under the Master Agreement (the "Fees & Expenses"). Capitalized terms
which are not defined in this Letter Agreement shall have the meanings ascribed
to such terms in the Master Agreement.
In consideration of the covenants and agreements hereinafter set forth,
the parties hereto agree as follows:
1. JWCI's share of each monthly invoice received from Synteract for the
Fees & Expenses shall calculated by dividing the total amount of
funding then available for data management under the NIH Grants by the
number of months in which such funds are intended to be utilized in
accordance with the terms of such NIH Grants (the "Remaining Grant
Period"). By way of example, if, upon the date an invoice is received
from Synteract, the total amount then available for data management
under the NIH Grants is $120,000, and the Remaining Grant Period is
twelve months, then the amount to be paid by JWCI shall be $10,000
(i.e., $120,000 / 12 months). Any additional funding for data
management related to the Studies which becomes available to JWCI
during the term of the Master Agreement under any renewals, extensions
or related grants from NIH, shall be added to the total amount
available for payment of the Fees & Expenses
2. CancerVax agrees that JWCI's financial liability to Synteract for the
Services shall be limited to the amounts available to JWCI under the
NIH Grants, payable as outlined in paragraph (1), above. CancerVax
further agrees to pay the difference, on a monthly basis, between the
NIH Grant funding and the Fees & Expenses.
This Letter Agreement may be executed in any number of counterparts,
each of which shall be deemed an original but which together shall constitute a
single instrument. If this letter contains principal terms and conditions which
are agreeable to you and you agree to be bound as described above, please
indicate by executing the enclosed copy of this letter and returning it to
CancerVax.
Very truly yours,
CancerVax Corporation
By: /s/ Xxxxx X. Xxxx
Xxxxx X. Xxxx
President and Chief Executive Officer
ACCEPTED AND AGREED:
Effective as of January 22, 2002
The Xxxx Xxxxx Cancer Institute
By: /s/ Xxxx Xxxxxx
Xxxx Xxxxxx
Executive Vice President, Finance & Administration
